Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTANS: Daratumumab + VMP in Asian NDMM
NCT03217812Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Nov 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03217812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217812.